| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Shelhigh Consent Agreement Stops Short Of Recall
Posted on 06/25/2007 22:38:35 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Shelhigh has agreed to stop distributing its implantable devices, roughly two months after FDA seized products made at the company’s Union, NJ, manufacturing facility. Under a court order signed last Friday, Shelhigh is required to hire independent consultants to inspect its facility and certify to FDA that everything is up to snuff. The order, though, stopped short of demanding a recall.
In April, FDA announced that it had uncovered “significant deficiencies” in Shelhigh’s manufacturing processes, expressing concern about the sterility of its devices, which include pediatric heart valves and conduits, surgical patches, dural patches, annuloplasty rings and arterial grafts. The agency seized what it could find at the Union facility, and ordered physicians to consider using alternative devices and to monitor patients already implanted with Shelhigh products.
Two weeks after the seizure, FDA asked Shelhigh to voluntarily recall its devices, but the company did not comply. At the time, Shelhigh’s marketing director, Douglas Goldman, told The Star Ledger that FDA has “no information to justify any action with regard to our devices,” adding, “Our products are safe and effective and have never been demonstrated to be unsterile.”
FDA took matters into its own hands by issuing a court order. The order signed last week, however, does not require Shelhigh to recall its devices, but rather, only to stop distributing them until FDA has approved the company’s plan for bringing its seized products and manufacturing processes into compliance. It’s at that point that Shelhigh will be allowed to resume manufacturing. Once that happens, the company is required to hire an independent auditor, who will report back to FDA, to inspect its facility at least once a year.
RELATED READING:
- FDA Seizes Shelhigh Devices
Med Tech Sentinel is a regular contributor to BioHealth Investor
_______________
Med Tech Sentinel
Shelhigh has agreed to stop distributing its implantable devices, roughly two months after FDA seized products made at the company’s Union, NJ, manufacturing facility. Under a court order signed last Friday, Shelhigh is required to hire independent consultants to inspect its facility and certify to FDA that everything is up to snuff. The order, though, stopped short of demanding a recall.
In April, FDA announced that it had uncovered “significant deficiencies” in Shelhigh’s manufacturing processes, expressing concern about the sterility of its devices, which include pediatric heart valves and conduits, surgical patches, dural patches, annuloplasty rings and arterial grafts. The agency seized what it could find at the Union facility, and ordered physicians to consider using alternative devices and to monitor patients already implanted with Shelhigh products.
Two weeks after the seizure, FDA asked Shelhigh to voluntarily recall its devices, but the company did not comply. At the time, Shelhigh’s marketing director, Douglas Goldman, told The Star Ledger that FDA has “no information to justify any action with regard to our devices,” adding, “Our products are safe and effective and have never been demonstrated to be unsterile.”
FDA took matters into its own hands by issuing a court order. The order signed last week, however, does not require Shelhigh to recall its devices, but rather, only to stop distributing them until FDA has approved the company’s plan for bringing its seized products and manufacturing processes into compliance. It’s at that point that Shelhigh will be allowed to resume manufacturing. Once that happens, the company is required to hire an independent auditor, who will report back to FDA, to inspect its facility at least once a year.
RELATED READING:
- FDA Seizes Shelhigh Devices
Med Tech Sentinel is a regular contributor to BioHealth Investor
_______________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- The Average Joe Investor
- Wishing Wealth
- Financial Skeptic
- Edmonton Real Estate
- Don't Mess With Taxes
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Tue Jul 22, 2008 09:23AM
Hedge funds have made billions this year shorting the banks, [read more]
Hedge funds have made billions this year shorting the banks, [read more]
<< My Home | TheMoneyBlogs Home